Michele Maio

Summary

Affiliation: Centro di Riferimento Oncologico
Country: Italy

Publications

  1. pmc Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?
    Ester Fonsatti
    Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, I, R, C, C, S, 33081 Aviano, Italy
    J Transl Med 2:21. 2004
  2. pmc Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer
    Ester Fonsatti
    Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, I, R, C, C, S, 33081 Aviano, Italy
    J Transl Med 2:18. 2004
  3. pmc Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
    Maria Colombino
    Unit of Cancer Genetics, Institute of Biomolecular Chemistry ICB, National Research Council CNR, Traversa La Crucca 3, Baldinca Li Punti 07100, Sassari, Italy
    J Transl Med 11:202. 2013
  4. pmc Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications
    L Sigalotti
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, IRCCS, 33081 Aviano, Italy
    Br J Cancer 86:979-82. 2002
  5. pmc Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications
    S Coral
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
    Br J Cancer 107:1116-24. 2012
  6. pmc Cancer classification using the Immunoscore: a worldwide task force
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, Paris, F 75006, France
    J Transl Med 10:205. 2012
  7. doi Update on the role of ipilimumab in melanoma and first data on new combination therapies
    Michele Maio
    Medical Oncology and Immunotherapy, Azienda Ospedaliera Universitaria Senese, Istituto Toscano Tumori, Siena, Italy
    Curr Opin Oncol 25:166-72. 2013
  8. pmc The cost of unresectable stage III or stage IV melanoma in Italy
    Michele Maio
    Medical Oncology and Immunotherapy, Azienda Ospedaliera Universitaria Senese, Istituto Toscano Tumori, Strada delle Scotte, 53100, Siena, Italy
    J Exp Clin Cancer Res 31:91. 2012
  9. doi Melanoma as a model tumour for immuno-oncology
    M Maio
    Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
    Ann Oncol 23:viii10-4. 2012
  10. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 10:83. 2012

Detail Information

Publications79

  1. pmc Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?
    Ester Fonsatti
    Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, I, R, C, C, S, 33081 Aviano, Italy
    J Transl Med 2:21. 2004
    ....
  2. pmc Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer
    Ester Fonsatti
    Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, I, R, C, C, S, 33081 Aviano, Italy
    J Transl Med 2:18. 2004
    ..In this review, the foreseeable clinical applications of CD105 in human cancer are discussed...
  3. pmc Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
    Maria Colombino
    Unit of Cancer Genetics, Institute of Biomolecular Chemistry ICB, National Research Council CNR, Traversa La Crucca 3, Baldinca Li Punti 07100, Sassari, Italy
    J Transl Med 11:202. 2013
    ..Prevalence and distribution of pathogenetic mutations in BRAF and NRAS genes were evaluated in multiple melanoma lesions from patients with different geographical origin within the same Italian population...
  4. pmc Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications
    L Sigalotti
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, IRCCS, 33081 Aviano, Italy
    Br J Cancer 86:979-82. 2002
    ....
  5. pmc Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications
    S Coral
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
    Br J Cancer 107:1116-24. 2012
    ..Thus, utilising a syngeneic mouse model, we investigated the remodelling of GEP of neoplastic and normal tissues induced by systemic administration of DHA...
  6. pmc Cancer classification using the Immunoscore: a worldwide task force
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, Paris, F 75006, France
    J Transl Med 10:205. 2012
    ..The results of this international validation may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune)...
  7. doi Update on the role of ipilimumab in melanoma and first data on new combination therapies
    Michele Maio
    Medical Oncology and Immunotherapy, Azienda Ospedaliera Universitaria Senese, Istituto Toscano Tumori, Siena, Italy
    Curr Opin Oncol 25:166-72. 2013
    ..This article provides an update on the therapeutic role of the monoclonal antibody ipilimumab in melanoma. Recent therapeutic combinations, as well as directions for further investigations, will also be discussed...
  8. pmc The cost of unresectable stage III or stage IV melanoma in Italy
    Michele Maio
    Medical Oncology and Immunotherapy, Azienda Ospedaliera Universitaria Senese, Istituto Toscano Tumori, Strada delle Scotte, 53100, Siena, Italy
    J Exp Clin Cancer Res 31:91. 2012
    ....
  9. doi Melanoma as a model tumour for immuno-oncology
    M Maio
    Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
    Ann Oncol 23:viii10-4. 2012
    ....
  10. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 10:83. 2012
    ....
  11. pmc The role of BRAF V600 mutation in melanoma
    Paolo A Ascierto
    Department of Melanoma, Istituto Nazionale Tumori Fondazione G, Pascale, Naples, Italy
    J Transl Med 10:85. 2012
    ....
  12. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  13. pmc A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
    Lisa H Butterfield
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA
    J Transl Med 6:81. 2008
    ..This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document...
  14. pmc Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology
    Hideaki Tahara
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    J Transl Med 7:45. 2009
    ..The institution of an interactive consortium for high throughput molecular monitoring of clinical trials with voluntary participation might provide cost-effective solutions...
  15. ncbi Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells
    Michele Maio
    Cancer Bioimmunotherapy Unit and Division of Anesthesia, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, via Pedemontana Occ le, 12, Aviano, 33081 Italy
    Cancer Immunol Immunother 51:9-14. 2002
    ....
  16. pmc The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward
    Michele Maio
    Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
    J Transl Med 6:8. 2008
    ..Here, we report the main issues discussed during the meeting...
  17. ncbi The Italian Network for Tumor Biotherapy (NIBIT). Sharing visions, goals and efforts at European level
    Michele Maio
    Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
    Tumori 94:179-81. 2008
    ..This article briefly summarizes the history and objectives of NIBIT, along with the actions so far taken by the Network...
  18. ncbi Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignangies
    M Maio
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto Nazionale di Ricovero e Cura a Carattere Scientifico, 33081 Aviano, Italy
    Front Biosci 6:D776-84. 2001
    ....
  19. doi Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma
    Michele Maio
    Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
    J Clin Oncol 28:1780-7. 2010
    ..In this large randomized study, we evaluated the efficacy and safety of combining Talpha1 with dacarbazine (DTIC) and interferon alfa (IFN-alpha) in patients with metastatic melanoma...
  20. ncbi Epigenetic targets for immune intervention in human malignancies
    Michele Maio
    Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano 33081, Italy
    Oncogene 22:6484-8. 2003
    ....
  21. ncbi Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications
    Sandra Coral
    Department of Medical Oncology, Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
    J Cell Physiol 207:58-66. 2006
    ..Altogether, the data obtained identify an immunomodulatory activity of 5-AZA-CdR in vivo and strongly suggest for its clinical use to design novel strategies of CTA-based chemo-immunotherapy for melanoma patients...
  22. doi Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma
    Elisabetta Fratta
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, PN, Italy
    J Cell Physiol 223:352-8. 2010
    ....
  23. ncbi Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy
    Luca Sigalotti
    Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
    Semin Oncol 32:473-8. 2005
    ....
  24. ncbi Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications
    Ester Fonsatti
    Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
    Clin Cancer Res 13:3333-8. 2007
    ..To investigate the potential of the DNA hypomethylating agent 5-aza-2'-deoxycytidine (5-aza-CdR) to improve the effectiveness of immunotherapeutic approaches against melanocyte differentiation antigens...
  25. ncbi Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma
    Luca Sigalotti
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
    J Immunother 25:16-26. 2002
    ....
  26. ncbi Epigenetic immunomodulation of hematopoietic malignancies
    Valter Gattei
    Clinical and Experimental Hematology Research Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
    Semin Oncol 32:503-10. 2005
    ....
  27. doi Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide
    Sandra Coral
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Aviano, Italy
    Cancer Immunol Immunother 62:605-14. 2013
    ....
  28. ncbi Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications
    Luca Sigalotti
    Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
    J Cell Physiol 212:330-44. 2007
    ....
  29. ncbi Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanoma
    Maresa Altomonte
    Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, I R C C S, Aviano, Italy
    J Cell Physiol 200:272-6. 2004
    ..This finding is consistent with evidences obtained in hematological malignancies, and suggests the potential usefulness of HLA-DR molecules to set-up new approaches of targeted therapy in metastatic melanoma...
  30. ncbi Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine
    Luca Sigalotti
    Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
    Cancer Res 64:9167-71. 2004
    ....
  31. doi Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
    Luana Calabro
    Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
    Lancet Oncol 14:1104-11. 2013
    ..We aimed to investigate the efficacy, safety, and immunological activity of the anti-CTLA4 monoclonal antibody, tremelimumab, in advanced malignant mesothelioma...
  32. pmc Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies
    Luca Sigalotti
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Via F, Gallini 2, Aviano, Italy
    J Transl Med 8:56. 2010
    ..On this path, an important improvement would possibly derive from the development of new generation epigenetic drugs characterized by much reduced systemic toxicities, higher bioavailability, and more specific epigenetic effects...
  33. ncbi 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications
    Sandra Coral
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, 33081 Aviano, Italy
    Clin Cancer Res 8:2690-5. 2002
    ....
  34. doi Epigenetics of melanoma: implications for immune-based therapies
    Elisabetta Fratta
    Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
    Immunotherapy 5:1103-16. 2013
    ..The aim of this review is to provide a comprehensive summary of melanoma epigenetics and the current use of epigenetic drugs in the clinical setting. ..
  35. ncbi Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications
    Luana Calabro
    Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
    J Cell Physiol 202:474-7. 2005
    ..These findings, and the concomitant up-regulation of HLA-class I antigens and ICAM-1 by 5-AZA-CdR, support its clinical use to set-up innovative chemo-immunotherapeutic approaches in PEL...
  36. ncbi Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1
    Michele Maio
    Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, 33081 Aviano, Italy
    J Clin Endocrinol Metab 88:748-54. 2003
    ..Serological survey may be useful as a way to identify patients with humoral immune response to NY-ESO-1 that provide a new attractive target for vaccine-based immunotherapy of MTC...
  37. pmc Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status
    Luca Sigalotti
    Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
    J Cell Physiol 215:287-91. 2008
    ....
  38. doi Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
    Anna Maria Di Giacomo
    Division of Medical Oncology and Immunotherapy, Department of Oncology, Istituto Toscano Tumori, University Hospital of Siena, Strada delle Scotte 14, 53100 Siena, Italy
    Cancer Immunol Immunother 62:1021-8. 2013
    ..We provide preliminary data describing the correlation between immunological parameters and response/survival among patients with advanced melanoma who received ipilimumab 10 mg/kg in an expanded access programme...
  39. pmc Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients
    Luca Sigalotti
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
    J Transl Med 9:78. 2011
    ..Genome-wide alterations in DNA methylation are a common event in cancer. This study aimed to define the prognostic value of genomic DNA methylation levels in stage III CM patients...
  40. pmc Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients
    Luca Sigalotti
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
    J Transl Med 10:185. 2012
    ..This study aimed to define the prognostic value of whole genome DNA methylation profiles in stage III CM...
  41. doi The biology of cancer testis antigens: putative function, regulation and therapeutic potential
    Elisabetta Fratta
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Via Franco Gallini 2, 33081 Aviano, Italy
    Mol Oncol 5:164-82. 2011
    ....
  42. doi Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications
    Luana Calabro
    Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
    Semin Oncol 37:460-7. 2010
    ..This review summarizes the main trials with ipilimumab and tremelimumab in tumors of different histotypes, excluding cutaneous melanoma, which is extensively described in other chapters of this issue of Seminars in Oncology...
  43. doi Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
    Riccardo Danielli
    Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Istituto Toscano Tumori, Strada delle Scotte, 53100 Siena, Italy
    Cancer Immunol Immunother 61:41-8. 2012
    ..The results indicate UM is a potential indication for ipilimumab treatment that should be further investigated in clinical trials...
  44. doi Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications
    Luana Calabro
    Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
    J Cell Physiol 226:2595-600. 2011
    ..These findings suggest that B7-H3 is a promising target for new immunotherapeutic strategies in MM, with particular emphasis in the epithelial variant...
  45. ncbi Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels
    Ester Fonsatti
    Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientific, Aviano 33081, Italy
    Oncogene 22:6557-63. 2003
    ..In addition, the potential usefulness of CD105 in tumor imaging and antiangiogenetic therapy has been well documented utilizing different animal models...
  46. doi Biology and clinical applications of CD40 in cancer treatment
    Ester Fonsatti
    Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
    Semin Oncol 37:517-23. 2010
    ..Preliminary findings emerging from clinical trials indicate that antibodies to CD40 can induce immune modulation and clinical responses in cancer patients...
  47. doi Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours
    Ester Fonsatti
    Division of Medical Oncology and Immunotherapy, Department of Oncology, Istituto Toscano Tumori, University Hospital of Siena, Strada delle Scotte 14, 53100 Siena, Italy
    Cardiovasc Res 86:12-9. 2010
    ..In this review, the main findings supporting the translation of antibody-based endoglin/CD105 targeting from pre-clinical studies to clinical applications in human cancer are summarized and discussed...
  48. doi Epigenetic markers of prognosis in melanoma
    Luca Sigalotti
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
    Methods Mol Biol 1102:481-99. 2014
    ....
  49. doi Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond
    Riccardo Danielli
    Department of Oncology, Division of Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
    Ann N Y Acad Sci 1270:8-12. 2012
    ..The main findings emerging from clinical trials and that support the therapeutic use of Tα1 in human melanoma are summarized and discussed...
  50. ncbi Differential levels of soluble endoglin (CD105) in myeloid malignancies
    Luana Calabro
    Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, I R C C S, Aviano, Italy
    J Cell Physiol 194:171-5. 2003
    ....
  51. doi Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
    Anna Maria Di Giacomo
    Division of Medical Oncology and Immunotherapy, Istituto Toscano Tumori, University Hospital of Siena, Siena, Italy
    Cancer Immunol Immunother 58:1297-306. 2009
    ..Moreover, because the patterns of response to ipilimumab differ from chemotherapy, we need to understand how and when patients may respond to treatment so that appropriate clinical decisions can be made...
  52. doi Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy
    Michele Maio
    Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
    Clin Cancer Res 21:4040-7. 2015
    ....
  53. doi Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study
    Luana Calabro
    Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
    Lancet Respir Med 3:301-9. 2015
    ..We therefore investigated the efficacy and safety of an intensified schedule of tremelimumab in patients with advanced malignant mesothelioma...
  54. doi Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)
    Anna Maria Di Giacomo
    Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Strada delle Scotte, 53100, Siena, Italy
    Cancer Immunol Immunother 60:467-77. 2011
    ..To evaluate the feasibility of ipilimumab treatment for metastatic melanoma outside the boundaries of clinical trials, in a setting similar to that of daily practice...
  55. doi The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications
    Anna Maria Di Giacomo
    Department of Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
    Semin Oncol 37:499-507. 2010
    ..This review provides an overview of current safety data on CTLA-4 antagonists and of available strategies to optimize their clinical use in cancer patients...
  56. pmc Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study
    Cristina Maccalli
    Italian Network for Biotherapy of Tumors NIBIT Laboratory, Siena, Italy Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy Unit of Immuno biotherapy of Melanoma and Solid Tumors, San Raffaele Foundation Center, Milan, Italy
    Oncoimmunology 5:e1071007. 2016
    ....
  57. doi ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies
    Riccardo Danielli
    Medical Oncology and Immunotherapy, Istituto Toscano Tumori, University Hospital of Siena, Siena, Italy
    Methods Mol Biol 1393:133-9. 2016
    ..Here, we report available data focusing on this issue and operative procedures to detect ICOS expression on circulating peripheral blood mononuclear cells during CTLA-4 blockade therapy. ..
  58. doi Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
    Anna Maria Di Giacomo
    Medical Oncology and Immunotherapy, Azienda Ospedaliera Universitaria Senese, Istituto Toscano Tumori, Siena, Italy
    Lancet Oncol 13:879-86. 2012
    ..We aimed to investigate the efficacy and safety of ipilimumab plus fotemustine in patients with metastatic melanoma with or without asymptomatic brain metastases...
  59. ncbi Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?
    Maresa Altomonte
    Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, via Pedemontana Occ le, 12, Aviano 33081, Italy
    Oncogene 22:6564-9. 2003
    ....
  60. doi Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study
    Riccardo Danielli
    Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy
    Cancer Immunol Immunother 64:999-1009. 2015
    ....
  61. doi Epigenetics meets immune checkpoints
    Alessia Covre
    Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy Epigen Therapeutics S r l, Pordenone, Italy
    Semin Oncol 42:506-13. 2015
    ....
  62. ncbi Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells
    Chiara De Nardo
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto Nazionale di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
    J Cell Physiol 190:200-6. 2002
    ..Further unveiling of the molecular mechanism that turns off CD59 expression in human melanoma cells will help to set-up more effective therapeutic strategies utilizing C-activating mAb in melanoma patients...
  63. ncbi Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
    Alexander M M Eggermont
    From Gustave Roussy Cancer Campus Grand Paris, Villejuif A M M E, C R, Aix Marseille University, Hopital de la Timone, Marseille J J G, Assistance Publique Hopitaux de Paris, Hopital Saint Louis, Paris C L, University Lille, INSERM Unité 1189, Centre Hospitalier Universitaire CHU Lille, Service de Dermatologie, Lille L M, and CHU Lyon, Lyon L T all in France the Oncology Institute of Veneto Istituto di Ricovero e Cura a Carattere Scientifico, Padua V C S, Istituto Nazionale Tumori Fondazione G Pascale, Naples P A A, Istituti Fisioterapici Ospitalieri, Rome V F, University Hospital of Siena, Istituto Toscano Tumori, Siena M M, and the European Institute of Oncology, Milan A T all in Italy University of Zurich Hospital, Zurich, Switzerland R D Memorial Sloan Kettering Cancer Center, New York J D W Aarhus University Hospital, Aarhus H S, and Odense University Hospital, Odense L B both in Denmark the Angeles Clinic and Research Institute, Los Angeles O H Oncology Specialists, College of Medicine
    N Engl J Med . 2016
    ..There were more immune-related adverse events with ipilimumab than with placebo. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00636168 , and EudraCT number, 2007-001974-10 .)...
  64. doi CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
    Luana Calabro
    Immunoterapia Oncologica, Dipartimento di Oncologia Medica, Istituto Toscano Tumori, Azienda Ospedaliera Universitaria Senese, Viale Mario Bracci n 16, 53100, Siena, Italy
    Cancer Immunol Immunother 64:105-12. 2015
    ..Finally, treatment with potentially effective, second-generation checkpoint(s) inhibiting mAb, as well future combination strategies in this deadly disease, will be discussed. ..
  65. doi Epigenetic drugs as immunomodulators for combination therapies in solid tumors
    Luca Sigalotti
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico Aviano, National Cancer Institute, Aviano, Italy
    Pharmacol Ther 142:339-50. 2014
    ..This review focuses on the immunomodulatory activity of epigenetic drugs and on their proposed clinical use in novel combined chemo-immunotherapeutic regimens for the treatment of solid tumors. ..
  66. ncbi European approach to antibody-based immunotherapy of melanoma
    Maresa Altomonte
    Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
    Semin Oncol 29:471-8. 2002
    ....
  67. doi Immune checkpoint blockade in malignant mesothelioma
    Luana Calabro
    Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy Electronic address
    Semin Oncol 42:418-22. 2015
    ..Herein, we highlight the clinical impact so far identified for these new immunomodulatory agents in MM patients and discuss their prospective use to design novel clinical trials...
  68. doi Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells
    Benjamin Weide
    Authors Affiliations Department of Dermatology, University Medical Center Department of Internal Medicine II, Section for Transplantation Immunology and Immunohematology, University of Tubingen, Tübingen German Cancer Research Center DKFZ German Cancer Consortium DKTK, Heidelberg Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg Essen, Essen, Germany Department of Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Italy and Skin Cancer Research Group, School of Public Health, Tropical Medicine and Rehabilitation Sciences, James Cook University, Townsville, Australia
    Clin Cancer Res 20:1601-9. 2014
    ....
  69. ncbi Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer
    Chiara Castelli
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G Venezian 1, 20133, Milan, Italy
    Cancer Immunol Immunother 53:227-33. 2004
    ..The immunological properties of these proteins and their implications for vaccine in human cancer will be discussed. Immunological and clinical data of phase I/II studies in melanoma and colorectal cancer patients will be reviewed...
  70. ncbi Methylation-regulated expression of HLA class I antigens in melanoma
    Ester Fonsatti
    Int J Cancer 105:430-1; author reply 432-3. 2003
  71. ncbi Heat shock proteins and their use as anticancer vaccines
    Giorgio Parmiani
    Istituto Nazionale Tumori, Milan, Italy
    Clin Cancer Res 10:8142-6. 2004
  72. ncbi Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings
    Filiberto Belli
    Unit of General Surgery 2, Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 20:4169-80. 2002
    ....
  73. ncbi The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma
    Annette Paschen
    Skin Cancer Unit of the German Cancer Research Center Heidelberg, University Clinics of Mannheim, Mannheim, Germany
    Clin Cancer Res 12:3297-305. 2006
    ..We asked whether abnormalities of chromosome 15, harboring the beta2m gene on 15q21, in addition to beta2m gene mutations, are causative for the HLA class I-negative phenotype of melanoma cells...
  74. doi Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis
    Marianna Sabatino
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Warren G Magnuson Clinical Center, Biometrics Research Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 1184, USA
    Cancer Res 68:122-31. 2008
    ..Our study provides important insights about the dynamics of cancer progression and supports the development of targeted anticancer therapies aimed against stable genetic factors that are maintained throughout the end stage of disease...
  75. ncbi Introduction: Melanoma: American and European perspectives on diagnosis and treatment
    Edward F McClay
    Melanoma Research Center of San Diego, Vista, CA, USA
    Semin Oncol 29:306-7. 2002
  76. ncbi 5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story
    Sandra Coral
    Cancer Res 67:2900-1; author reply 2901-2. 2007
  77. ncbi A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients
    Lorenzo Pilla
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Cancer Immunol Immunother 55:958-68. 2006
    ..Clinical activity was limited to SD. However, both immunological and clinical responses were not improved as compared with those recorded in a previous study investigating HSPPC-96 monotherapy...
  78. ncbi Is it the primetime for endoglin (CD105) in the clinical setting?
    Michele Maio
    Cardiovasc Res 69:781-3. 2006